New treatment for Parkinson's disease

December 2015
Mayo Clinic Health Letter;Dec2015, Vol. 33 Issue 12, p4
The article discusses the development of the gel Duopa which aims to provide continuous delivery of the medication levodopa for people with advanced Parkinson's disease without causing dyskinesias. The gel is delivered through a tube inserted into a small hole in the abdomen. Results of the trial indicated that those who received continuous infusion of the gel experienced significantly less off time than those who took the pills.


Related Articles

  • Will Abbot Navigate With the Aviator? Mendosa, David // Diabetes Health;Apr2006, Vol. 15 Issue 4, p54 

    Presents an update on the approval application of Abbot Diabetes Care for its FreeStyle Navigator Continuous Glucose Monitor in the U.S. market as of April 2006. Design features of the insulin pump product; Statement issued by Holly Kulp, divisional vice president for Abbott; Information on a...

  • FDA Introspection. Delporte, Christopher // Orthopedic Design & Technology;May/Jun2010, Vol. 6 Issue 3, p8 

    In this article, the author discusses the latest guidelines for medical device issued by U.S. Food and Drugs Administration (FDA). It notes that medical device manufacturers are now addressing their concerns concerning the FDA guidelines in approving medical products, which make the clearance...

  • Uncertainties in the pharmacotherapy of Parkinson's disease and how to solve them. Overstall, P. W.; Clarke, C. E. // Gerontology;2002, Vol. 48 Issue 1, p30 

    The causative relationship between levodopa and the long-term motor complications of therapy, along with the possibility that levodopa may be toxic to dopaminergic neurones in vivo, has led to a move away from its use in early Parkinson’s disease. Alternatives such as amantadine and the...

  • Nutritional assessment in patients with Parkinson's disease treated with duodenal infusion of L-dopa (preliminary data). Galletti, Rosalba; Sabet, Dina; Segre, Olivia; Aimasso, Umberto; Finocchiaro, Etta; Fadda, Maurizio; Mancino, Vittoria; Rivetti, Marina; Ossola, Marta; Zibetti, Maurizio; Lopiano, Leonardo // Nutritional Therapy & Metabolism;Jan-Mar2011, Vol. 29 Issue 1, p47 

    Parkinson's disease is a neurodegenerative disease characterized by tremor, bradykinesia, rigidity and postural instability. In recent years, the direct administration of levodopa (L-dopa) into the duodenum through a gastrojejunostomy has proved to be an effective strategy to stabilize motor...

  • Immunoglobulin replacement therapy by slow subcutaneous infusion. Berger, Melvin; Cupps, Thomas R.; Fauci, Anthony S.; Berger, M; Cupps, T R; Fauci, A S // Annals of Internal Medicine;Jul80 Part 1, Vol. 93 Issue 1, p55 

    Reports the successful use of a small portable pump to administer increased amounts of immune serum globulin by slow subcutaneous infusion. Description of the infusion pumps; Background on the patients; Benefit of the infusion technique.

  • Rigel Medical introduces infusion pump testing in new free booklet.  // Operating Theatre Journal;Sep2014, Issue 288, p4 

    No abstract available.

  • Eliminating Source of Error in IV Pump Testing. Ruiter, Karl // 24x7;Jan2016, Vol. 21 Issue 1, p14 

    The article focuses on controlling factors resulting in error in the testing of IV infusion pumps including variations in water temperature, impact of air drafts on scale readings, and following manufacturer recommendations on use, cleaning, and storage.

  • New portable infusion pump for prolonged subcutaneous administration of opioid analgesics in patients with advanced cancer.  // British Medical Journal (Clinical Research Edition);6/7/1986, Vol. 292 Issue 6534, p1496 

    Examines the durability of Act-a-Pump infusion pump in Great Britain. Use of pump for opioid analgesic administrator; Advantages of Act-a-Pack; Features of the infusion pumps.

  • Ziprasidone in Parkinson's disease psychosis. Connemann, Bernhard J.; Schönfeldt-Lecuona, Carlos // Canadian Journal of Psychiatry;Jan2004, Vol. 49 Issue 1, p73 

    Presents a letter to the editor concerning the use of ziprasidone in treating Parkinson's disease psychosis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics